Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2014-02-08
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild AGITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-02-25 (study day 18.0); relationship: REMOTE
mild
assessed
Mild ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2014-03-22 (study day 43.0); relationship: PROBABLE
Data queries
No data queries.